KisoJi Biotechnology
Laval-ouest
About KisoJi Biotechnology
KisoJi Biotechnology is an early-stage biotechnology company developing antibodies for the treatment of various cancers. Unlike traditional industry methods, the full spectrum of antibody diversity can be identified and visualized, allowing for the pinpointing of clusters with desired characteristics and the optimization of lead candidate selection. The antibody platform includes multi-species single-domain antibody transgenic mice, AI-driven antibody fingerprinting to find the best fit with specific epitopes on any target, and a toolkit for creating robust, easily manufacturable multi-specific antibodies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $40.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2024)
- Website: kisojibiotech.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Canonical: https://fsome.com/organization/kisoji-biotechnology-122665 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.